Literature DB >> 31186897

Nonsurgical options for localized hepatocellular carcinoma.

John Ha1, Robert J Wong2.   

Abstract

Entities:  

Year:  2017        PMID： 31186897      PMCID： PMC6499223          DOI： 10.1002/cld.662

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  16 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

2.  Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.

Authors:  Ryosuke Tateishi; Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Yukihiro Koike; Tomonori Fujishima; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

3.  Emerging trends in hepatocellular carcinoma incidence and mortality.

Authors:  Basile Njei; Yaron Rotman; Ivo Ditah; Joseph K Lim
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

Review 4.  Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.

Authors:  Laila Lobo; Danny Yakoub; Omar Picado; Caroline Ripat; Fiorella Pendola; Rishika Sharma; Rana ElTawil; Deukwoo Kwon; Shree Venkat; Loraine Portelance; Raphael Yechieli
Journal:  Cardiovasc Intervent Radiol       Date:  2016-09-01       Impact factor: 2.740

5.  Early palliative care for patients with metastatic non-small-cell lung cancer.

Authors:  Jennifer S Temel; Joseph A Greer; Alona Muzikansky; Emily R Gallagher; Sonal Admane; Vicki A Jackson; Constance M Dahlin; Craig D Blinderman; Juliet Jacobsen; William F Pirl; J Andrew Billings; Thomas J Lynch
Journal:  N Engl J Med       Date:  2010-08-19       Impact factor: 91.245

6.  Microwave versus Radiofrequency Ablation Treatment for Hepatocellular Carcinoma: A Comparison of Efficacy at a Single Center.

Authors:  Theodora A Potretzke; Timothy J Ziemlewicz; J Louis Hinshaw; Meghan G Lubner; Shane A Wells; Christopher L Brace; Parul Agarwal; Fred T Lee
Journal:  J Vasc Interv Radiol       Date:  2016-03-24       Impact factor: 3.464

7.  Association between the Medicare hospice benefit and health care utilization and costs for patients with poor-prognosis cancer.

Authors:  Ziad Obermeyer; Maggie Makar; Samer Abujaber; Francesca Dominici; Susan Block; David M Cutler
Journal:  JAMA       Date:  2014-11-12       Impact factor: 56.272

8.  A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.

Authors:  Kai Feng; Jun Yan; Xiaowu Li; Feng Xia; Kuansheng Ma; Shuguang Wang; Ping Bie; Jiahong Dong
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Race/Ethnicity-specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis and its Impact on Receipt of Curative Therapies.

Authors:  John Ha; Melissa Yan; Maria Aguilar; Michele Tana; Benny Liu; Catherine T Frenette; Taft Bhuket; Robert J Wong
Journal:  J Clin Gastroenterol       Date:  2016 May-Jun       Impact factor: 3.062
View more
  1 in total

1.  Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors.

Authors:  Paul Rogowski; Rieke von Bestenbostel; Franziska Walter; Katrin Straub; Lukas Nierer; Christopher Kurz; Guillaume Landry; Michael Reiner; Christoph Josef Auernhammer; Claus Belka; Maximilian Niyazi; Stefanie Corradini
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.